About Glykogen
GlykoGen Limited was formed and registered in Scotland, in October 2016 by its founder Dr Kimberley Mackenzie. A pipeline of engineered monoclonal antibodies that have efficacy against cancer targets will be developed. GlykoGen will create, screen, modify and demonstrate the action of the antibodies against cancer cells. The antibodies, together with the accompanying data package, will be licensed to pharmaceutical companies who will take them forward as candidates for therapeutic treatments.
Sectors
- antibodies